论文部分内容阅读
【目的】分析2010年1月至2011年9月间全球季节性H3N2流感病毒血凝素(Hemagglutinin,HA)和神经氨酸酶(Neuraminidase,NA)基因的演变和分子特征,为流感病毒的防制提供分子信息依据。【方法】搜集期间季节性H3N2流感病毒HA和NA基因的完整核苷酸序列,分别绘制两基因编码序列的进化树;推导出相应的氨基酸序列,统计不同毒株间氨基酸位点差异并分析重要功能位点的变化。【结果】在136条完整的片段4和131条片段6中,2条HA和1条NA序列源自猪群流感病毒,剩余的序列根据进化特征可被分为两群。相比疫苗毒株,发生在HA和NA蛋白抗原位点的平均差异数分别为5.33和2.01个,3个毒株分别在HA宿主受体结合位点和二硫键及NA耐药位点出现突变,多数毒株的糖基化位点增多。江苏毒株和广东毒株分别属于群1和群2,且两省毒株间在HA蛋白抗原位点的差异数从7到13个不等。【结论】2010年1月至2011年9月间的全球季节性H3N2病毒主要呈现两种基因进化特征。因抗原性差异对疫苗开发具有指导作用,而多数毒株的抗原性检测信息仍然未知,但从抗原位点和糖基化位点的变异情况来看,多数毒株的抗原性可能已经变化,为判断是否形成新的流行株,应开展进一步的抗原性检测;并且各地区卫生行政部门应根据耐药位点的变化,制定相应的抗病毒治疗措施。
【Objective】 To analyze the evolution and molecular characteristics of the global seasonal H3N2 influenza virus hemagglutinin (HA) and neuraminidase (NA) genes from January 2010 to September 2011, System to provide molecular information basis. 【Method】 The complete nucleotide sequences of HA and NA genes of seasonal H3N2 influenza virus were collected and the phylogenetic trees of the two gene coding sequences were drawn respectively. The corresponding amino acid sequences were deduced and the differences of amino acid positions among different strains were analyzed and analyzed. Functional site changes. 【Result】 In 136 complete fragments 4 and 131, fragment 6, two HA and one NA sequence were derived from swine influenza virus, and the remaining sequences could be divided into two groups according to the evolutionary characteristics. Compared with the vaccine strain, the average number of differences between the antigenic sites of HA and NA proteins were 5.33 and 2.01, respectively. The three strains appeared at the HA host receptor binding sites and the disulfide and NA resistant sites, respectively Mutation, the majority of strains of glycosylation sites increased. Jiangsu strain and Guangdong strain belong to group 1 and group 2, respectively, and the difference in HA protein antigenic loci of the two provinces varied from 7 to 13. 【Conclusion】 The global seasonal H3N2 virus from January 2010 to September 2011 mainly showed two kinds of gene evolution characteristics. The differences of antigenicity may guide vaccine development, but the antigenicity detection information of most strains is still unknown. However, the antigenicity of most of the strains may have changed from the variation of antigenic site and glycosylation site, In order to determine whether a new epidemic strain should be formed, further antigenicity tests should be carried out; and the health administrative departments in all regions should formulate corresponding antiviral treatment measures according to the change of the drug-resistant loci.